Samsung Health Makes Sleep Coaching Easier to Start and Tailors Weekly Guidance - samsung.com

Samsung Electronics America today announced a major update to the Samsung Health app, making Sleep Coaching1 even easier by lowering the data required to get started. The update also delivers more personalized sleep guidance and expanded running program2 tiers, while nutrition features including Scan Meal beta service and nutrition curriculums will be offered in the U. S. While Sleep Tracking tells users how they slept, Sleep Coaching is designed to encourage better sleep, by helping users incorporate their personal goals and data into their daily habits.

Samsung Electronics today announced a major update to the Samsung Health app, making Sleep Coaching1 even easier to start by lowering the data requirement to begin. The update also delivers more personalized sleep guidance and expanded running program tiers to help users build lasting, healthier routines. While sleep tracking tells users how they slept, sleep coaching helps them sleep better by turning personal sleep goals and data into daily habits.

Continuous glucose monitors (CGMs) could transform diabetes management for millions of Americans with type 2 diabetes who don't take insulin, according to findings published in the New England Journal of Medicine. The clinical trial found that adults using CGMs spent approximately five additional hours each day within their target blood sugar range compared with those receiving routine care. Nearly twice as many CGM users also achieved an A1c level below 7%, a common treatment goal for people with diabetes.

Patients who wore noise-canceling headphones during minimally invasive gynecological surgery were significantly less likely to experience postoperative nausea and vomiting (PONV), suggest findings from a randomized clinical trial presented at the Anesthesiology 2026 annual meeting.

“Beyond Detecting Cancer Recurrence: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? An exciting new study published in The Oncologist highlights the clinical potential of Signatera Genome, a whole-genome sequencing (WGS)-based, tumor-informed circulating tumor DNA (ctDNA) assay, not only for detecting molecular residual disease (MRD), but also for potentially informing adjuvant treatment decisions.